MX9704575A - Compuestos quimicos. - Google Patents
Compuestos quimicos.Info
- Publication number
- MX9704575A MX9704575A MX9704575A MX9704575A MX9704575A MX 9704575 A MX9704575 A MX 9704575A MX 9704575 A MX9704575 A MX 9704575A MX 9704575 A MX9704575 A MX 9704575A MX 9704575 A MX9704575 A MX 9704575A
- Authority
- MX
- Mexico
- Prior art keywords
- enzyme
- chemical compounds
- interaction
- prodrug
- reversed
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Developing Agents For Electrophotography (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- External Artificial Organs (AREA)
- Mechanical Coupling Of Light Guides (AREA)
Abstract
Sistema mejorados para la terapia de profármaco de enzima como objetivo, especialmente dirigida al anticuerpo (ADEPT), en la cual la enzima es una forma mutada de una enzima huésped, en la cual la enzima huésped natural, tal como la ribonucleasa, reconoce su sustrato natural por una interaccion de par ionico y esta interaccion es invertida ('polaridad inversa') en el diseño de la enzima mutada y el profármaco complementario.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9426192.2A GB9426192D0 (en) | 1994-12-23 | 1994-12-23 | Chemical compounds |
GBGB9516810.0A GB9516810D0 (en) | 1995-08-16 | 1995-08-16 | Chemical compounds |
PCT/GB1995/002991 WO1996020011A1 (en) | 1994-12-23 | 1995-12-21 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9704575A true MX9704575A (es) | 1997-10-31 |
Family
ID=26306259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9704575A MX9704575A (es) | 1994-12-23 | 1995-12-21 | Compuestos quimicos. |
Country Status (23)
Country | Link |
---|---|
US (1) | US5985281A (es) |
EP (1) | EP0806964B1 (es) |
JP (1) | JP3805365B2 (es) |
KR (1) | KR100270650B1 (es) |
CN (1) | CN1095677C (es) |
AT (1) | ATE222124T1 (es) |
AU (1) | AU701916B2 (es) |
BR (1) | BR9510490B1 (es) |
CA (1) | CA2205091A1 (es) |
CZ (1) | CZ195297A3 (es) |
DE (1) | DE69527805T2 (es) |
ES (1) | ES2181805T3 (es) |
FI (1) | FI972683A0 (es) |
HU (1) | HUT77450A (es) |
IL (1) | IL116511A0 (es) |
MX (1) | MX9704575A (es) |
NO (1) | NO972882L (es) |
NZ (1) | NZ297529A (es) |
PL (1) | PL184031B1 (es) |
RU (1) | RU2189251C2 (es) |
SK (1) | SK80997A3 (es) |
TR (1) | TR199501654A2 (es) |
WO (1) | WO1996020011A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2227040A1 (en) * | 1995-08-16 | 1997-03-06 | Zeneca Limited | Chemical compounds |
SG71046A1 (en) | 1996-10-10 | 2000-03-21 | Connector Systems Tech Nv | High density connector and method of manufacture |
WO1998035988A1 (en) * | 1997-02-14 | 1998-08-20 | Zeneca Limited | Proteins |
GB9703201D0 (en) * | 1997-02-15 | 1997-04-02 | Zeneca Ltd | Chemical compounds |
GB9709421D0 (en) * | 1997-05-10 | 1997-07-02 | Zeneca Ltd | Chemical compounds |
US6361774B1 (en) | 1999-09-17 | 2002-03-26 | Immunomedics, Inc. | Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug |
US20040117863A1 (en) * | 1998-09-18 | 2004-06-17 | Edge Michael D. | Transgenically produced fusion proteins |
AU763628B2 (en) * | 1998-09-18 | 2003-07-31 | Immunomedics Inc. | Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug |
JP2003509040A (ja) * | 1999-09-17 | 2003-03-11 | ジェンジム トランスジェニックス コーポレイション | 遺伝子導入により産生された融合タンパク質 |
EP1565564A4 (en) * | 2002-11-27 | 2006-06-07 | Gtc Biotherapeutics Inc | STILK-STABILIZED ANTIBODIES PRODUCED IN MILK AND METHOD FOR THE MANUFACTURE THEREOF |
US20080019905A9 (en) * | 2005-02-18 | 2008-01-24 | Strome Scott E | Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection |
DK1945666T3 (da) * | 2005-10-21 | 2013-07-01 | Genzyme Corp | Antistoffer med forøget antistofafhængig cellulær cytotoksicitetsaktivitet, fremgangsmåder til fremstilling af disse og anvendelse heraf |
US20080031866A1 (en) * | 2006-06-20 | 2008-02-07 | Eichenbaum Gary M | Method for modulating the pharmacokinetics and metabolism of a therapeutic agent |
EP2037954A4 (en) * | 2006-06-20 | 2011-09-14 | Janssen Pharmaceutica Nv | METHOD FOR MODULATING PHARMACOKINETICS AND METABOLISM OF THERAPEUTIC USE |
EP2792670A1 (en) * | 2006-10-03 | 2014-10-22 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of mustards and related compounds with very high skin penetration rates |
GB0709333D0 (en) * | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
WO2009134389A2 (en) * | 2008-05-01 | 2009-11-05 | Gtc Biotherapeutics, Inc. | An anti-cd137 antibody as an agent in the treatment of inflammatory conditions |
US10745492B1 (en) | 2019-04-03 | 2020-08-18 | Ark Diagnostics, Inc. | Antibodies to symmetrically dimethylated arginine analytes and use thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8705477D0 (en) * | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5632990A (en) * | 1988-04-22 | 1997-05-27 | Cancer Research Campaign Tech. Ltd. | Treatment for tumors comprising conjugated antibody A5B7 and a prodrug |
GB8809616D0 (en) * | 1988-04-22 | 1988-05-25 | Cancer Res Campaign Tech | Further improvements relating to drug delivery systems |
US5433955A (en) * | 1989-01-23 | 1995-07-18 | Akzo N.V. | Site specific in vivo activation of therapeutic drugs |
CA2025899A1 (en) * | 1989-01-23 | 1990-07-24 | Reinhard Bredehorst | Site specific in-vivo activation of therapeutic drugs |
CA2127126A1 (en) * | 1992-01-30 | 1993-08-05 | Helen M. Wilks | Chiral synthesis with modified enzymes |
GB9323429D0 (en) * | 1993-11-12 | 1994-01-05 | Wellcome Found | Therapy |
US5389537A (en) * | 1994-01-21 | 1995-02-14 | Wisconsin Alumni Research Foundation | Nuclease having altered specificity |
-
1995
- 1995-12-21 CZ CZ971952A patent/CZ195297A3/cs unknown
- 1995-12-21 AT AT95941214T patent/ATE222124T1/de not_active IP Right Cessation
- 1995-12-21 AU AU42697/96A patent/AU701916B2/en not_active Ceased
- 1995-12-21 HU HU9702280A patent/HUT77450A/hu unknown
- 1995-12-21 CA CA002205091A patent/CA2205091A1/en not_active Abandoned
- 1995-12-21 DE DE69527805T patent/DE69527805T2/de not_active Expired - Lifetime
- 1995-12-21 JP JP52028496A patent/JP3805365B2/ja not_active Expired - Fee Related
- 1995-12-21 SK SK809-97A patent/SK80997A3/sk unknown
- 1995-12-21 WO PCT/GB1995/002991 patent/WO1996020011A1/en not_active Application Discontinuation
- 1995-12-21 RU RU97112396/14A patent/RU2189251C2/ru not_active IP Right Cessation
- 1995-12-21 NZ NZ297529A patent/NZ297529A/xx not_active IP Right Cessation
- 1995-12-21 BR BRPI9510490-9A patent/BR9510490B1/pt not_active IP Right Cessation
- 1995-12-21 PL PL95320964A patent/PL184031B1/pl not_active IP Right Cessation
- 1995-12-21 EP EP95941214A patent/EP0806964B1/en not_active Expired - Lifetime
- 1995-12-21 CN CN95196986A patent/CN1095677C/zh not_active Expired - Fee Related
- 1995-12-21 US US08/860,882 patent/US5985281A/en not_active Expired - Lifetime
- 1995-12-21 KR KR1019970704250A patent/KR100270650B1/ko not_active IP Right Cessation
- 1995-12-21 MX MX9704575A patent/MX9704575A/es not_active IP Right Cessation
- 1995-12-21 ES ES95941214T patent/ES2181805T3/es not_active Expired - Lifetime
- 1995-12-22 TR TR95/01654A patent/TR199501654A2/xx unknown
- 1995-12-22 IL IL11651195A patent/IL116511A0/xx not_active IP Right Cessation
-
1997
- 1997-06-19 FI FI972683A patent/FI972683A0/fi unknown
- 1997-06-20 NO NO972882A patent/NO972882L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NZ297529A (en) | 1999-07-29 |
EP0806964A1 (en) | 1997-11-19 |
SK80997A3 (en) | 1998-02-04 |
IL116511A0 (en) | 1996-07-23 |
PL184031B1 (pl) | 2002-08-30 |
CN1095677C (zh) | 2002-12-11 |
BR9510490A (pt) | 1998-01-13 |
TR199501654A2 (tr) | 1996-07-21 |
WO1996020011A1 (en) | 1996-07-04 |
CZ195297A3 (en) | 1997-12-17 |
BR9510490B1 (pt) | 2010-10-05 |
EP0806964B1 (en) | 2002-08-14 |
AU701916B2 (en) | 1999-02-11 |
NO972882L (no) | 1997-08-19 |
AU4269796A (en) | 1996-07-19 |
DE69527805T2 (de) | 2003-04-24 |
CN1171054A (zh) | 1998-01-21 |
ATE222124T1 (de) | 2002-08-15 |
JPH10511547A (ja) | 1998-11-10 |
JP3805365B2 (ja) | 2006-08-02 |
HUT77450A (hu) | 1998-04-28 |
US5985281A (en) | 1999-11-16 |
ES2181805T3 (es) | 2003-03-01 |
FI972683A (fi) | 1997-06-19 |
RU2189251C2 (ru) | 2002-09-20 |
CA2205091A1 (en) | 1996-07-04 |
KR100270650B1 (ko) | 2000-11-01 |
PL320964A1 (en) | 1997-11-24 |
NO972882D0 (no) | 1997-06-20 |
FI972683A0 (fi) | 1997-06-19 |
DE69527805D1 (de) | 2002-09-19 |
TR199501654A3 (es) | 1996-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9704575A (es) | Compuestos quimicos. | |
AU7261994A (en) | Hydrazino-type radionuclide chelators having an n3s configuration | |
AU6154996A (en) | Bacterial production of hydrophobic polypeptides | |
HUT76556A (en) | Novel agent for controlling cell activity | |
AU2844892A (en) | Process for lysing mycobacteria | |
FI943389A0 (fi) | Bacillus-lajista saatu ksylanaasi, tällaisen ksylanaasin ja muiden proteiinien ekspressiovektori, niiden isäntäorganismit ja käyttö | |
AU2724492A (en) | Antibodies in immunosuppression | |
AU7760094A (en) | Process for lysing mycobacteria | |
CS21192A3 (en) | Complex containing precipitation factor ix | |
AU4339289A (en) | A system for cooperatively reassigning duties in a multiple controller environment | |
AU569896B2 (en) | Process for the dissolution of peptides and proteins | |
MY116010A (en) | Termiticide and method for termite control using the same | |
GB2309033A (en) | Chemical compounds | |
AU1559501A (en) | Apoptosis inducing proteinaceous substance | |
AU591254B2 (en) | Control system for inclined impact-type surface seismic source | |
DK0870015T3 (da) | Xylanaser, gener, der koder for disse, samt anvendelser deraf | |
AU5648094A (en) | Process for the preparation of aqueous nicotinaldehyde | |
TW326033B (en) | Cyanobenzenesulfenyl halide and process for preparation of 3-substituted benzisothiazole using the same | |
AU8011498A (en) | Novel ppgpp synthetase and expression systems for improved production of proteinof interest | |
AU561319B2 (en) | Plasmid and microorganism for constitutive creatinaminohydrolase formation | |
AU633083B2 (en) | Silica for dentifrice compositions, more particularly compatible with organic amino compounds | |
WO1998030687A3 (de) | Srcr domäne-enthaltendes protein | |
Lin et al. | Surface Processing of Components and Tools by MEVVA Source Ion Impplantation | |
AU1207292A (en) | Halohydrocarbon-free timed-release coating solution for pharmaceutical preparations | |
AU1911283A (en) | 1,2,3,4 - tetrahydro-1-aminomethyl-4-phenyl - isoquinolines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
HC | Change of company name or juridical status |
Owner name: ARADIGM CORPORATION |
|
PD | Change of proprietorship |
Owner name: LONDON BIOTECHNOLOGY LIMITED |
|
MM | Annulment or lapse due to non-payment of fees |